γδ T 细胞调节小细胞肺癌中的抗肿瘤免疫
γδ T cells modulate anti-tumor immunity in small cell lung cancer.
我们的发现表明,活化的γδ T细胞可能是SCLC治疗的有价值靶点。
英文原题:Identification of a six-gene signature to predict survival and immunotherapy effectiveness of gastric cancer.
我们发现了一个6基因特征来预测GC患者的OS。这一风险特征被证明是指导临床实践的有价值的临床预测工具。
胃癌(GC)是全球第五大常见恶性肿瘤,也是第二大肿瘤致死原因。尽管有分期指南和标准治疗方案,GC患者的生存和对治疗的反应仍存在显著异质性。因此,近年来越来越多的研究探讨了用于筛选高危GC患者的预后模型。
我们研究了GEO和TCGA数据集中GC组织与邻近非肿瘤组织之间的DEGs。然后通过单因素Cox回归分析在TCGA队列中进一步筛选候选DEGs。随后,利用LASSO回归生成DEGs的预后模型。我们使用ROC曲线、Kaplan-Meier曲线和风险评分图来评估该signature的性能和预后能力。ESTIMATE、xCell和TIDE算法用于探索风险评分与免疫景观之间的关系。作为最后一步,本研究利用临床特征和预后模型开发了nomogram。
TCGA中有3211个DEGs,GSE54129中有2371个DEGs,GSE66229中有627个DEGs,GSE64951中有329个DEGs被选为候选基因,并与DEGs取交集。总共,通过单因素Cox回归分析在TCGA队列中进一步筛选出208个DEGs。随后,利用LASSO回归生成6个DEGs的预后模型。外部验证显示出良好的预测效能。我们基于六基因特征研究了风险模型、免疫评分和免疫细胞浸润之间的相互作用。高风险组相对于低风险组表现出显著升高的ESTIMATE评分、免疫评分和基质评分。CD4+记忆T细胞、CD8+初始T细胞、共同淋巴祖细胞、浆细胞样树突状细胞、γδT细胞和B细胞浆细胞的比例在低风险组中显著富集。根据TIDE,低风险组的TIDE评分、排除评分和功能障碍评分低于高风险组。最后,本研究利用临床特征和预后模型开发了列线图。
BACKGROUND: Gastric cancer (GC) ranks as the fifth most prevalent malignancy and the second leading cause of oncologic mortality globally. Despite staging guidelines and standard treatment protocols, significant heterogeneity exists in patient survival and response to therapy for GC. Thus, an increasing number of research have examined prognostic models recently for screening high-risk GC patients. METHODS: We studied DEGs between GC tissues and adjacent non-tumor tissues in GEO and TCGA datasets. Then the candidate DEGs were further screened in TCGA cohort through univariate Cox regression analyses. Following this, LASSO regression was utilized to generate prognostic model of DEGs. We used the ROC curve, Kaplan-Meier curve, and risk score plot to evaluate the signature's performance and prognostic power. ESTIMATE, xCell, and TIDE algorithm were used to explore the relationship between the risk score and immune landscape relationship. As a final step, nomogram was developed in this study, utilizing both clinical characteristics and a prognostic model. RESULTS: There were 3211 DEGs in TCGA, 2371 DEGs in GSE54129, 627 DEGs in GSE66229, and 329 DEGs in GSE64951 selected as candidate genes and intersected with to obtain DEGs. In total, the 208 DEGs were further screened in TCGA cohort through univariate Cox regression analyses. Following this, LASSO regression was utilized to generate prognostic model of 6 DEGs. External validation showed favorable predictive efficacy. We studied interaction between risk models, immunoscores, and immune cell infiltrate based on six-gene signature. The high-risk group exhibited significantly elevated ESTIMATE score, immunescore, and stromal score relative to low-risk group. The proportions of CD4 + memory T cells, CD8 + naive T cells, common lymphoid progenitor, plasmacytoid dentritic cell, gamma delta T cell, and B cell plasma were significantly enriched in low-risk group. According to TIDE, the TIDE scores, exclusion scores and dysfunction scores for low-risk group were lower than those for high-risk group. As a final step, nomogram was developed in this study, utilizing both clinical characteristics and a prognostic model. CONCLUSION: In conclusion, we discovered a 6 gene signature to forecast GC patients' OS. This risk signature proves to be a valuable clinical predictive tool for guiding clinical practice.
MEMBER ACCOUNT
登录成功会直接打开下一页。